We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

235 hedge funds and large institutions have $2.67B invested in Amicus Therapeutics in 2021 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 85 increasing their positions, 73 reducing their positions, and 54 closing their positions.

New
Increased
Maintained
Reduced
Closed

237% more call options, than puts

Call options by funds: $18.8M | Put options by funds: $5.59M

40% more funds holding in top 10

Funds holding in top 10: 57 (+2)

16% more repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 73

3% less capital invested

Capital invested by funds: $2.74B → $2.67B (-$68.9M)

1.98% less ownership

Funds ownership: 106.07%104.09% (-2%)

9% less funds holding

Funds holding: 259235 (-24)

41% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 54

Holders
235
Holders Change
-24
Holders Change %
-9.27%
% of All Funds
4.09%
Holding in Top 10
7
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+40%
% of All Funds
0.12%
New
32
Increased
85
Reduced
73
Closed
54
Calls
$18.8M
Puts
$5.59M
Net Calls
+$13.2M
Net Calls Change
+$8.3M
Name Holding Trade Value Shares
Change
Change in
Stake
RWML
226
RAFFA WEALTH MANAGEMENT, LLC
District of Columbia
$925 -$10 -1 -1%
ED
227
Exane Derivatives
France
$822
TPCW
228
TD Private Client Wealth
New York
$405
MF
229
Magnetar Financial
Illinois
$182 -$109K -11,155 -37%
Nisa Investment Advisors
230
Nisa Investment Advisors
Missouri
$103 +$81K +8,300 +342%
ClearBridge Investments
231
ClearBridge Investments
New York
-$28.6M -2,894,879 Closed
GGHC
232
Gilder Gagnon Howe & Co
New York
-$22.8M -2,305,432 Closed
EAM
233
Eagle Asset Management
Florida
-$16.3M -1,616,670 Closed
CS
234
Candriam SCA
Luxembourg
-$13.6M -615,124 Closed
California Public Employees Retirement System
235
California Public Employees Retirement System
California
-$5.45M -551,478 Closed
First Trust Advisors
236
First Trust Advisors
Illinois
-$2.85M -288,291 Closed
TCM
237
Tygh Capital Management
Oregon
-$1.34M -135,510 Closed
FCM
238
Farallon Capital Management
California
-$988K -100,000 Closed
QIM
239
Quantitative Investment Management
Virginia
-$970K -98,248 Closed
KOCAA
240
Knights of Columbus Asset Advisors
Connecticut
-$946K -95,709 Closed
Mirae Asset Global Investments
241
Mirae Asset Global Investments
South Korea
-$935K -94,611 Closed
MSL
242
Mackay Shields LLC
New York
-$877K -88,705 Closed
JF
243
Jump Financial
Illinois
-$810K -81,910 Closed
Tudor Investment Corp
244
Tudor Investment Corp
Connecticut
-$625K -63,292 Closed
Walleye Trading
245
Walleye Trading
New York
-$616K -63,096 Closed
GAMA
246
Graticule Asia Macro Advisors
New York
-$622K -63,000 Closed
HT
247
HAP Trading
New York
-$578K -59,224 Closed
GCP
248
GSA Capital Partners
United Kingdom
-$554K -56,077 Closed
CAM
249
ClariVest Asset Management
California
-$482K -48,838 Closed
SSA
250
Schonfeld Strategic Advisors
New York
-$455K -46,104 Closed

FOLD Hedge Fund Activity: Q2 2021 in Review

235 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q2 2021, worth a combined $2.67B — down 2.5% from $2.74B a quarter earlier.

Sellers outnumbered buyers: 54 funds closed out of FOLD and 32 opened new positions — a net loss of 22 holders — while 73 trimmed existing stakes and 85 added.

The largest buyer was Point72 Asset Management, adding an estimated $36M. The largest seller was Janus Henderson Group, cutting an estimated $39M.

  • 235 institutional investors held Amicus Therapeutics (FOLD) as of Q2 2021, down from 259 in Q1 2021.
  • Funds reported $2.67B of Amicus Therapeutics stock for Q2 2021, down 2.5% quarter-over-quarter.
  • 32 funds opened new Amicus Therapeutics positions in Q2 2021 and 54 closed out, a net change of -22 holders.
  • The largest Amicus Therapeutics buyer in Q2 2021 was Point72 Asset Management, an estimated $36M added.
  • The largest Amicus Therapeutics seller in Q2 2021 was Janus Henderson Group, an estimated $39M sold.

Based on aggregated 13F filings for Q2 2021.